CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase II Pilot Trial of an Indoleamine 2,3, Dioxygenase-1 (IDO1) Inhibitor (INCB024360) Plus a Multipeptide Melanoma Vaccine (MELITAC 12.1) in Patients With Advanced Melanoma

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT01961115
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:36:54.127850+00:00
Published At: 2018-02-07T00:00:00+00:00
Record Updated At: 2018-06-08
Results Posted At: 2018-02-07
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Mucosal Melanoma", "Recurrent Melanoma", "Recurrent Uveal Melanoma", "Stage IIIA Skin Melanoma", "Stage IIIA Uveal Melanoma", "Stage IIIB Skin Melanoma", "Stage IIIB Uveal Melanoma", "Stage IIIC Skin Melanoma", "Stage IIIC Uveal Melanoma", "Stage IV Skin Melanoma", "Stage IV Uveal Melanoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2018-06-08"
protocolSection.identificationModule.nctId: "NCT01961115"
protocolSection.identificationModule.officialTitle: "A Phase II Pilot Trial of an Indoleamine 2,3, Dioxygenase-1 (IDO1) Inhibitor (INCB024360) Plus a Multipeptide Melanoma Vaccine (MELITAC 12.1) in Patients With Advanced Melanoma"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2018-02-07"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.